Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.
Odyssey Health (OTC: ODYY) continues to dedicate its operational strategy to the acquisition and creation of vital medical products. “Odyssey’s portfolio includes medical device candidates and pharmaceuticals in development that address conditions such as heart disease, foreign body-induced choking, neurodegenerative disorders and brain injury. A drug product designed to treat mild traumatic injuries in the first minutes after an incident is progressing through a Phase 1 human clinical trial following preclinical testing in laboratory animals that provided encouraging data, the CEO Michael Redmond in an interview in June,” a recent article. bed. “No U.S. Food and Drug Administration (“FDA”)-approved drugs exist at this time, creating a particular opportunity for the company. The other drug substance is a new compound intended to treat the neurodegenerative disease from Niemann-Pick, which leaves patients with an average lifespan of five to 20 years after diagnosis.
To see the full article, visit https://ibn.fm/zqPL0
About Odyssey Health Inc. (formerly Odyssey Group International Inc.)
Odyssey Health is a medical company focused on developing life-enhancing medical solutions. Odyssey’s corporate mission is to develop and commercialize exceptional technologies that deliver meaningful medical solutions. The company is focused on technologies that offer superior clinical utility, have substantial market opportunity, and deliver strong returns to its valued shareholders and partners. For more information, visit the company’s website at www.OdysseyHealthInc.com.
NOTICE TO INVESTORS: The latest news and updates relating to ODYY can be found in the company’s newsroom at https://ibn.fm/ODYY
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full range of corporate communications solutions. As a multi-faceted financial news and content distribution company with an extensive team of journalists and writers, BMW is uniquely positioned to better serve private and public companies seeking to reach large audiences in investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 major syndication outlets across the country. By reducing the information overload in today’s market, BMW provides customers with unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS alerts from BioMedWire, text “Biotech” to 844-397-5787 (US cell phones only)
For more information, please visit https://www.BioMedWire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork